tiprankstipranks
Raffles Medical Group Ltd (RAFLF)
OTHER OTC:RAFLF

Raffles Medical Group (RAFLF) Stock Forecast & Price Target

17 Followers
See the Price Targets and Ratings of:

RAFLF Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Raffles
Medical Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RAFLF Stock 12 Month Forecast

There Are No Analyst Ratings for RAFLF In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

RAFLF Financial Forecast

RAFLF Earnings Forecast

The previous quarter’s earnings for RAFLF were $0.01.
The previous quarter’s earnings for RAFLF were $0.01.

RAFLF Sales Forecast

The previous quarter’s earnings for RAFLF were $249.93M.
The previous quarter’s earnings for RAFLF were $249.93M.

Detailed List of Analyst Forecasts​

Analyst Performance
Any
Any
Analyst Rating
Any
Any
Upside / Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Phillip Securities
$0.71
Hold
$0.71
(-3.55% Downside)
Reiterated
02/28/24
Analysts Offer Insights on Healthcare Companies: Raffles Medical Group (Other OTC: RAFLF), Agilent (NYSE: A) and Karuna Therapeutics (NASDAQ: KRTX)
UOB Kay Hian
$0.85
Hold
$0.85
(15.54% Upside)
Reiterated
02/27/24
Hold Rating on Raffles Medical Group Amidst Margin Pressure and Mixed Financial Performance
DBS
$0.74
Hold
$0.74
(0.47% Upside)
Reiterated
02/27/24
Raffles Medical Group: Hold Rating with Balanced Risk-Reward Amid Normalization and China Expansion Factored In
CGS-CIMB
$0.89
Buy
$0.89
(20.56% Upside)
Reiterated
01/04/24
Optimistic Outlook for Raffles Medical Group Amid Rising Patient Loads and Profitable CTF Operations
Nomura
$1.19$1.04
Buy
$1.04
(40.66% Upside)
Reiterated
11/07/23
Raffles Medical Group Ltd (RFMD:SP) (RAFLF) PT Lowered to SGD1.40 at Nomura/InstinetNomura/Instinet analyst Raghavendra Divekar lowered the price target on Raffles Medical Group Ltd (RFMD:SP) (OTC: RAFLF) to SGD1.40 (from SGD1.60) while maintaining a Buy rating.
Maybank
$1.23
Buy
$1.23
(65.77% Upside)
Reiterated
08/01/23

Best Analysts Covering Raffles Medical Group

Which Analyst Should I Follow If I Want to Buy RAFLF and Sell After:
1 Month
xxx
Success Rate
0/5 ratings generated profit
0%
Average Return
-5.50%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -5.50% per trade.
3 Months
xxx
Success Rate
1/5 ratings generated profit
20%
Average Return
-4.80%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -4.80% per trade.
1 Year
Eric OngMaybank
Success Rate
0/5 ratings generated profit
0%
Average Return
-24.36%
reiterated a buy rating 12 months ago
Copying Eric Ong's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -24.36% per trade.
2 Years
xxx
Success Rate
0/5 ratings generated profit
0%
Average Return
-28.14%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -28.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RAFLF Analyst Recommendation Trends

Rating
Sep 23
Oct 23
Nov 23
Jan 24
Feb 24
Strong Buy
7
7
4
2
1
Buy
0
0
0
1
1
Hold
0
0
3
3
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
7
6
8
In the current month, RAFLF has received 2 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. RAFLF average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

RAFLF Stock Forecast FAQ

What is RAFLF’s average 12-month price target, according to analysts?
Currently, no data Available
What is RAFLF’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for RAFLF, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is RAFLF a Buy, Sell or Hold?
      Currently, no data Available
      What is Raffles Medical Group Ltd’s price target?
      Currently, no data Available
      What do analysts say about Raffles Medical Group Ltd?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of RAFLF?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis